S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

NYSEAMERICAN:NNVCNanoViricides Stock Price, Forecast & News

$6.34
+0.18 (+2.92 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.11
Now: $6.34▼
$6.40
50-Day Range N/A
52-Week Range
$1.27
Now: $6.34▼
$19.20
Volume357,130 shs
Average Volume2.54 million shs
Market Capitalization$67.55 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as injectable and oral anti-influenza nanoviricide drug for H7N9, Bird Flu H5N1, other Highly Pathogenic Influenzas, Epidemic Influenzas, and Seasonal Influenzas; DengueCide, an anti-dengue nanoviricide which is in pre-clinical development; and HIVCide, an anti-human immunodeficiency virus drug candidate. It is also developing HerpeCide, a skin cream for the treatment of cold sores and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.42 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:NNVC
Previous SymbolNYSEMKT:NNVC
CUSIPN/A
CIK1379006
Webwww.nanoviricides.com
Phone+1-203-9376137

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees7
Outstanding Shares10,655,000
Market Cap$67.55 million
Next Earnings Date8/28/2020 (Estimated)
OptionableOptionable
$6.34
+0.18 (+2.92 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NNVC News and Ratings via Email

Sign-up to receive the latest news and ratings for NNVC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NanoViricides (NYSEAMERICAN:NNVC) Frequently Asked Questions

When is NanoViricides' next earnings date?

NanoViricides is scheduled to release its next quarterly earnings announcement on Friday, August 28th 2020.
View our earnings forecast for NanoViricides.

How were NanoViricides' earnings last quarter?

NanoViricides Inc (NYSEAMERICAN:NNVC) released its quarterly earnings results on Monday, June, 22nd. The company reported ($0.30) earnings per share for the quarter.
View NanoViricides' earnings history.

When did NanoViricides' stock split? How did NanoViricides' stock split work?

Shares of NanoViricides reverse split before market open on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of NanoViricides stock prior to the reverse split would have 5 shares after the split.

Has NanoViricides been receiving favorable news coverage?

Media stories about NNVC stock have been trending very positive this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. NanoViricides earned a media sentiment score of 4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about NanoViricides.

Are investors shorting NanoViricides?

NanoViricides saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 673,000 shares, an increase of 65.7% from the June 30th total of 406,200 shares. Based on an average daily volume of 1,440,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 7.1% of the company's stock are short sold.
View NanoViricides' Current Options Chain.

Who are some of NanoViricides' key competitors?

Some companies that are related to NanoViricides include BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), Trilogy International Partners (TRL), Recce Pharmaceuticals (RCE), Futura Medical (FUM), Vita Life Sciences (VLS), Pharmaxis (PXS), Sareum (SAR), China Pharma (CPHI), Antisense Therapeutics (ANP), Cathay International (CTI), Avivagen (VIV), Patrys (PAB) and N4 Pharma (N4P).
View all competitors.

What other stocks do shareholders of NanoViricides own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Micron Technology (MU), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Domino's Pizza (DPZ), AbbVie (ABBV), Novavax (NVAX), Vaxart (VXRT) and NVIDIA (NVDA).

Who are NanoViricides' key executives?

NanoViricides' management team includes the following people:
  • Dr. Anil R. Diwan, Chairman, Pres & Sec. (Age 60)
  • Ms. Meeta R. Vyas SB, MBA, Chief Financial Officer (Age 60)
  • Dr. Eugene Seymour, Chief Exec. Officer Emeritus (Age 78)
  • Dr. Randall W. Barton Ph.D., Chief Scientific Officer & Chief Regulatory Officer (Age 72)
  • Dr. Irach B. Taraporewala, Consultant & Director (Age 63)

What is NanoViricides' stock symbol?

NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."

Who are NanoViricides' major shareholders?

NanoViricides' stock is owned by many different retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.24%).
View institutional ownership trends for NanoViricides.

Which institutional investors are buying NanoViricides stock?

NNVC stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for NanoViricides.

How do I buy shares of NanoViricides?

Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NanoViricides' stock price today?

One share of NNVC stock can currently be purchased for approximately $6.34.

How big of a company is NanoViricides?

NanoViricides has a market capitalization of $67.55 million. NanoViricides employs 7 workers across the globe.

What is NanoViricides' official website?

The official website for NanoViricides is www.nanoviricides.com.

How can I contact NanoViricides?

NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The company can be reached via phone at +1-203-9376137.

This page was last updated on 8/7/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.